(Q33344657)

26 July 2017

title

Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours (English)

1 reference

26 July 2017

1 reference

1 reference

Androulakis N

1

1 reference

26 July 2017

Kouroussis C

2

1 reference

26 July 2017

Mavroudis D

3

1 reference

26 July 2017

Kakolyris S

4

1 reference

26 July 2017

Souglakos J

5

1 reference

26 July 2017

Agelaki S

6

1 reference

26 July 2017

Kalbakis K

7

1 reference

26 July 2017

Malas K

8

1 reference

26 July 2017

Pallis A

9

1 reference

26 July 2017

Samonis G

10

1 reference

26 July 2017

Georgoulias V

11

1 reference

26 July 2017

publication date

1 October 2002

1 reference

European Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

38

1 reference

26 July 2017

issue

15

1 reference

26 July 2017

page(s)

1992-1997

1 reference

Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Phase I trial of weekly paclitaxel in advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Breast cancer therapies in development. A review of their pharmacology and clinical potential.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Sterically stabilized liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900168-5

7 January 2021

10.1016/S0959-8049(02)00168-5

Identifiers

DOI

1 reference

26 July 2017

1 reference